London-based pharmaceutical giant AstraZeneca plans to acquire MedImmune, the region's hallmark biotech company, in a $15.6 billion cash deal expected to close in the next two months.
Subscribe to:
Post Comments (Atom)
London-based pharmaceutical giant AstraZeneca plans to acquire MedImmune, the region's hallmark biotech company, in a $15.6 billion cash deal expected to close in the next two months.
No comments:
Post a Comment